TY - JOUR T1 - RapiD_AI: A framework for Rapidly Deployable AI for novel disease & pandemic preparedness JF - medRxiv DO - 10.1101/2022.08.09.22278600 SP - 2022.08.09.22278600 AU - Alexey Youssef AU - Tingting Zhu AU - Anshul Thakur AU - Peter Watkinson AU - Peter Horby AU - David W Eyre AU - David A Clifton Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/18/2022.08.09.22278600.abstract N2 - COVID-19 is unlikely to be the last pandemic that we face. According to an analysis of a global dataset of historical pandemics from 1600 to the present, the risk of a COVID-like pandemic has been estimated as 2.63% annually or a 38% lifetime probability. This rate may double over the coming decades. While we may be unable to prevent future pandemics, we can reduce their impact by investing in preparedness. In this study, we propose RapiD_AI : a framework to guide the use of pretrained neural network models as a pandemic preparedness tool to enable healthcare system resilience and effective use of ML during future pandemics. The RapiD_AI framework allows us to build high-performing ML models using data collected in the first weeks of the pandemic and provides an approach to adapt the models to the local populations and healthcare needs. The motivation is to enable healthcare systems to overcome data limitations that prevent the development of effective ML in the context of novel diseases. We digitally recreated the first 20 weeks of the COVID-19 pandemic and experimentally demonstrated the RapiD_AI framework using domain adaptation and inductive transfer. We (i) pretrain two neural network models (Deep Neural Network and TabNet) on a large Electronic Health Records dataset representative of a general in-patient population in Oxford, UK, (ii) fine-tune using data from the first weeks of the pandemic, and (iii) simulate local deployment by testing the performance of the models on a held-out test dataset of COVID-19 patients. Our approach has demonstrated an average relative/absolute gain of 4.92/4.21% AUC compared to an XGBoost benchmark model trained on COVID-19 data only. Moreover, we show our ability to identify the most useful historical pretraining samples through clustering and to expand the task of deployed models through inductive transfer to meet the emerging needs of a healthcare system without access to large historical pretraining datasets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and in part by the InnoHK Project Programme 3.2; Human Intelligence and AI Integration (HIAI) for the Prediction and Intervention of CVDs; and the Warning System at Hong Kong Centre for Cerebro cardiovascular Health Engineering (COCHE). DAC is an Investigator in the Pandemic Sciences Institute, University of Oxford, Oxford, UK. DWE is a Big Data Institute Robertson Fellow. TZ was supported by the Engineering for Development Research Fellowship provided by the Royal Academy of Engineering. AY acknowledges the generous support of the Rhodes Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, or InnoHK_ITC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Electronic Health Records data was used in this research. We used de-identified data from the Infections in Oxfordshire Research Database (IORD). This dataset has approvals from the relevant Research Ethics Committee, Health Research Authority, and Confidentiality Advisory Group. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -